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1. Introduction 
1.1 Helicobacter pylori infection 
One-half of the world′s population is infected with Helicobacter pylori (H. pylori), a gram 
negative bacterium which is responsible for various major upper digestive tract diseases. H. 
pylori is one of the most common bacterial pathogens in humans, who are the only known 
host of H. pylori The human stomach is considered the reservoir of this bacteria.  
H. pylori has been cultured from saliva, dental plaque, vomitus, and diarrheal stool 
demonstrating that the bacterium is potentially transmissible by these routes. The main 
route of transmission is not yet clearly understood. 
H. pylori transmission is believed to be mainly familial, and there is epidemiological 
evidence that shows that the infection spreads via person-to-person contact (14). Moreover, 
potential reservoirs of bacterium are through to be animals who are in close contacts with 
humans: cats, dogs, pigs, and birds. There is also the hypothesis that the most predominant 
mode of transmission is mother-to-child via contact with regurgitated gastric juice from  the 
mother′s mouth. The most common accepted routes of transmission are fecal-oral in 
developing countries, and gastro-oral route in developed countries. There are many risk 
factors for H. pylori infection including: overpopulation/congested houses, family sizes, 
unsafe sources of water, and low socioeconomic status (17).  
The common risk factors for H. pylori infection is:  
 crowding 
 low level of personal hygiene  
 low family income 
 unclean drinking water 
 lack of toilet facilities during childhood 
 low educational level 
 previous gastrointestinal endoscopy 
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H. pylori infection is recognized as a worldwide problem as it causes chronic gastritis, peptic 
ulcer disease, and Mucosa-Associated Lymphoid Tissue lymphoma. H. pylori is also a major 
risk factor for gastric cancer. The global burden of gastric cancer is considerable but varies in 
different countries, with more than 70% of cases occurring in developing countries 
especially in Eastern Asia. In 2008, it was estimated that there would be just under one 
million new cases of stomach cancer (Tab.1) Stomach cancer accounts for 7.8% of the all total 
cancers worldwide, and it is currently the fourth most common malignancy in the world, 
behind lung cancer, breast cancer, and colon cancer. Stomach cancer is more common in 
men (640 000) than in women (348 000), and half of the world’s stomach cancers occur in 
Eastern Asia and China. The highest mortality rates are estimated in Eastern Asia (28.1 per 
100,000 in men, 13.0 per 100,000 in women), and the lowest in Northern America (2.8 and 
1.5, respectively). High mortality rates are present in both sexes in Europe, and in Central 
and South America.  
 
Estimated 
numbers 
(thousands) 
Men Women Both sexes 
Cases Deaths Cases Deaths Cases Deaths 
World 640 463 348 273 988 736 
More developed 
regions 
173 110 101 70 274 180 
Less developed 
regions 
467 353 246 202 713 55 
China 315 231 148 121 463 352 
European Union 
(EU-27) 
50 37 32 24 82 61 
Globocan 2008 
Table 1. Stomach Cancer Incidence and Mortality Worldwide  
The prevalence of H. pylori ranges from <10-20% in the USA, 40% in Germany, and 30-40% 
in England to more than 70% in Eastern Europe or even up to 90% Asia and Africa. The 
percentile of infection is also higher in rural areas than in big cities (5).  
There are differences in H. pylori prevalence between high and low-income countries 
because H. pylori infection is strongly related to economic conditions (17). H. pylori incidence 
also increases with age largely due to the birth cohort effects. The children are re-infected 
more frequently than adults and because the close contact between young children, 
especially among siblings and children under the age of 5. In developing countries infection 
occurs in the first years of life and increases successively involving almost 90% of the 50-
year-olds. In developed countries it affects only a small percentage of children below 10 
years of age and does not exceed 40% in adults. It has been suggested that treating infected 
children reduces the transmission of infection and ultimately reduces the gastric cancer in 
adults, but the role of potential H. pylori eradication for the prevention of gastric cancer is 
still unknown.  
The effects of H. pylori infection on human gastric physiology are complex. Presence of the 
bacteria induces chronic inflammation via the release of chemokines and cytokines. H. pylori 
infection also stimulates the human immune system, causing T and B lymphocytes, along 
with neutrophils and monocytes to produce antibodies (Ig G and IgA) and cytokines (TNF 
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alpha, interleukin). This immune response is unable to eliminate the pathogen and leads to 
persistent gastric mucosal damage as more neutrophils, lymphocytes, and plasma cells are 
recruited to chronic inflammatory sites (Tab.2). 
 
Activation of limphocyte Stimulation of neutrophile and monocyte 
 Lymphocyte B (↑Ig G, ↑IgA) in human 
blood 
 ↑Histamine 
 Lymphocyte T (IL-2,IL-8, TNF alfa)  ↑ Interleukin (IL-1,IL-6, IL-8) 
  ↑ TNF alfa 
  ↑ Interferon 
  ↑ Prostoglandin E2 
Table 2. The human immune system response to H. pylori infection 
The virulence of the bacteria depends on the presence of the cag pathogenicity island which 
is a 35-40 kb genomic fragment containing 29 genes. The cagA protein is a well-known 
virulence marker encoded by the cagA gene. The presence of this gene has been associated 
with both duodenal ulcers and gastric cancer. CagA is phosphorylated and binds to SHP-2 
tyrosine phosphatase and induces the intracellular signaling processes. 
Another virulence marker is 95-kd vacuolating cytotoxin VacA which is related to the cag 
pathogenicity island. The VacA toxin opens the membrane channels of gastric epithelial cells 
to give the bacteria nutrients, and the mitochondrial membrane releases cytochrome c to 
induce apoptosis. 
The H. pylori infection can be diagnosed by invasive and noninvasive testing (Tab.3). ”Test 
and treat strategy” everywhere in H. pylori infection is recommended for patients with 
uninvestigated persistent dyspepsia less than 45, 50 or 55 years depending on country’s 
guidelines without any alarm features (24, 25, 26). The “test and treat strategy” is based on 
non-invasive testing of H. pylori infection. 
 
H. pylori diagnostic tests 
Invasive Non-invasive 
Gastroscopy  
 standard videoendoscopy 
 high magnifying endoscopy 
 chromoendoscopy  
Serology  
 near patient tests (HelicoTest) 
 ELISA 
Rapid urease test (CLO test) UBT test C13, C14 
Histology (Giemsa staining) HP stool antigen test (HPSA) 
 polyclonal antibody–based ELISA 
 monoclonal antibody –based ELISA 
Microbiology Culture  Gastropanel 
 H. pylori antibodies 
 Pepsinogen I, II 
 Gastrin 17 
 
Table 3. Diagnostic modalities of H. pylori infection 
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1.2 Functional dyspepsia 
The detection of current H. pylori infection is becoming more important clinically, especially 
in young patients, because the eradication of infection is likely to affect the natural course of 
the disease and modify the risk of gastric cancer. Early detection and eradication of H. pylori 
in the population will decrease major upper tract organic diseases as well (13).  
Strategies to improve the management of H. pylori infection in the dyspeptic population 
with upper gastrointestinal symptoms have been shown to reduce mortality in the 
population caused by H. pylori infection. It is good to note that there is still more research 
needed regarding serology tests in young dyspeptic patients.  
The Maastricht III-2005 Consensus report recommended serology as an alternative option 
for countries with a high prevalence of H. pylori infection (19, 20). The two serology tests that 
are most often used are the ELISA test and the near patients tests. The serology tests have 
the lowest cost per correct diagnosis at low (30%), intermediate (60%), and high prevalence 
(90%) of H. pylori infection but their diagnostic accuracy is lower than other noninvasive 
tests. The Urea Breath Test (UBT) is more costly, more time consuming, and needs special 
preparation by the patient, such as fasting and cessation of antibiotics, proton pump 
inhibitors (PPI), and H2 blockers. The doctors who care for undiagnosed dyspeptic patients 
need to be aware of the value of these serology tests in young patients. 
2. Dyspepsia and gastrointestinal symptoms  
Gastrointestinal symptoms are common, with up to one in three people in population-based 
studies reporting symptoms from the gastrointestinal tract (Tab.4). Research published in 
2008 in Sweden has shown a prevalence of symptoms from upper and lower gastrointestinal 
tract in adult population study even up to 60%. Symptom flux over time provides primary 
care physicians with a significant workload.  
 
Gastrointestinal symptoms Pain modalities 
1. Acid regurgitation 
2. Belching 
3. Burning feeling rising from the stomach 
up towards the neck 
4. Dysphagia 
5. Early satiety 
6. Heartburn 
7. Nausea 
8. Loss of appetite 
9. Loss of weight 
10. Pain behind the breast bone 
11. Uncomfortable feeling of fullness 
12. Vomiting (recurrent) 
1. Aching 
2. Butterflies  
3. Burning sensation 
4. Cramp 
5. Colic 
6. Gripes 
7. Pain 
8. Tenderness 
9. Twinge 
10. Stitch 
11. Sinking feeling 
Table 4. The 12 general upper gastrointestinal symptoms from Carlsson & Drossman.  
11 abdominal discomfort or pain modalities. 
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Gastrointestinal symptoms have been grouped into several entities (Fig.2). Depending on 
the symptoms profile, dyspeptic symptoms ranged from 15-40% in the population, reflux 
symptoms 15-25%, and irritable bowel symptoms 10-20%. About 14% of all patients will 
have dyspeptic, reflux, and irritable bowel symptoms when they are presenting in the 
primary care setting.  
 
Fig. 2. The prevalence of reflux, dyspeptic and irritable bowel complaints in the general 
population. 
Data was collected from two neighboring communities in Northern Sweden, Kalix and 
Haparanda, with 18,408 and 10,580 inhabitants, respectively (Kalixandra Study) has showed 
that most gastrointestinal complaints classified as reflux, dyspeptic, or irritable bowel 
complaints lasts over 6 month.  
The short-term fluctuation of gastrointestinal symptoms in the general population is a fact 
(Fig.3). Reflux complaints are slightly more stable in comparison to the dyspeptic symptoms 
or irritable bowel complaints. During times of stress and emotional problems dyspeptic 
problems can be more severe and cause more problems for the patient, but only a fraction of 
sufferers will seek medical care (4). It is important to remember that troublesome 
gastrointestinal complaints remained present in approximately 90% of subjects in all 
symptoms groups if not diagnosed and treated. 
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Fig. 3. Fluctuation of gastrointestinal complains in the short term from 4 weeks to 6 months. 
3. Undiagnosed dyspepsia 
Dyspepsia is very common and most patients will experience symptoms occasionally 
(Fig.4).  
 
Fig. 4. Prevalence of dyspepsia in the community. 
If the symptoms are chronic and recurrent medical management is needed. If the patients 
have symptoms occurring more than twice a week or lasting for over 4 weeks medical help 
is needed because of the major decrease in quality of life (2). 
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The life impairment and impact of undiagnosed dyspepsia on health-related quality of life 
(HRQOL) is significantly lower in dyspeptic patients than in healthy controls (0,85+/-0,17 vs 
0,95+/-0,12) p<0,0001 (15). 
Dyspepsia is diagnosed as a syndrome consisting of pain or discomfort centered in the 
upper abdomen (epigastric pain), burning, fullness, discomfort, early satiety, nausea, 
vomiting, and belching.  
Many patients with undiagnosed dyspepsia are usually young and there is overlap of 
symptoms and findings in performed investigations regarding to most functional symptoms 
like Irritable Bowel Syndrome or Functional Heartburn (9).  
If alarm symptoms occur in patients with undiagnosed dyspepsia, upper gastroscopy is 
needed (Tab.5). 
 
 Signs and symptoms of upper gastrointestinal bleeding 
 Unexplained anemia 
 Unexplained weight loss 
 Progressive dysphagia 
 Recurrent vomiting 
 Progression of symptoms 
 Previous gastric surgery 
 Family history of gastrointestinal cancer 
 <45,50, or 55 years of age (depending on country) 
Table 5. Alarm symptoms for uninvestigated dyspepsia and indications for upper 
gastrointestinal endoscopy. 
The epidemiology of dyspepsia can influence of many factors such as: cultural differences in 
reporting of symptoms of dyspepsia, socio-economic status, cigarette smoking, H. pylori 
infection, use of non-steroidal anti-inflammatory drugs, and alcohol consumption (Tab.6).  
 
 Main Risk Factors:  Odds Ratio 
 H. pylori infection  OR 1,21 (CI;1,03-1,42) 
 Cigarette smoking 20/day  OR 1,55 (CI;1,29-1,86) 
 Unemployment  OR 2,18 (CI2,86-2,56) 
 Daily use of ASA/NSAID    OR 2,33 (CL;1,72-3,15) 
 Others: Alcohol consumption, social status, 
life style factors, level of education 
 
Table 6. Risk factors for dyspepsia in a general population a total 10 007 aged  40-64 years. 
Research has shown that patients profiles and risk factors are important in the management 
of dyspepsia, and its role is increasing with the patients age. Common use of non-steroidal 
anti-inflammatory drugs, high prevalence of H. pylori infection in many countries, and the 
increasing prevalence of smoking in the young population make dyspepsia a very common 
ailment (31).  
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Initial management with prompt endoscopy slightly more effective (3,7,8) compared to the 
“test and treat” approach for inducing resolution of symptoms, but is not as cost effective as 
the  “test and treat” strategy (Tab.7). 
 
Outcomes RRR (CI) 
Presence of symptoms  5% (1 to 8) significant difference favours 
for endoscopy 
 Standardised mean difference (95% CI) 
Total dyspepsia symptoms score -0,11 (-028 to 0,07) 
 Weighted mean difference (CI) 
Additional cost of prompt endoscopy (US 
dollars) 
$389 (276-502) significant differences 
favour "test and treat strategy" 
Table 7. Initial management of dyspepsia with prompt endoscopy v “test and treat” strategy 
at 12 month. 
There is an overlap of symptoms and finding structural abnormalities in upper endoscopy, 
however about 60% of all endoscopies performed will not find any structural changes in 
upper digestive track (Fig.5).  
 
Fig. 5. Abnormal finding at upper digestive track during performing gastroscopy. 
40% of all patients with dyspeptic complaints will have some small mucosal changes in 
upper gastrointestinal tract. Ford et al. provide the first meta-analysis of individual patients 
of 5 management trials. Their results strongly support the “test and treat” strategy in terms 
of cost effectiveness. The prevalence of organic dyspepsia as classified by endoscopy 
increased with the patient’s age (23). A proportion of patients have an underlying organic 
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cause for their symptoms such as peptic ulcer disease or reflux esophagitis. However, only 
3% of people in the population-based study were found to have an organic disease 
diagnosed in the general health care system.  
Peptic ulcer was found in only 3.9% of all subjects with upper abdominal symptoms in 
population based study by Bernersen et al. Aro et al. found that 4.1% of the subjects have 
peptic ulcers and minority of those with gastroesophageal reflux disease were found to have 
esophagitis on endoscopy which still is the most commonly found change on  this 
procedures (29). 
There is great debate in the medical community about whether gastrointestinal symptoms in 
the general population should be regarded as a disease or not. Many cases of epigastric pain 
are diagnosed as functional dyspepsia (FD) without any organic changes found in upper 
endoscopy. FD can be diagnosed if the symptoms are chronic and not caused by another 
organic, systemic, or metabolic disease. Many of those with dyspeptic symptoms will have 
functional dyspepsia, gastrointestinal motor abnormalities, or altered visceral sensation. FD 
can be considered as bio-psychological disorder causing a dysregulation of the brain-gut 
axis (1).  
A meta-analysis of 9 trials evaluating a total of 2541 patients with FD found a modest but 
significant benefit to H. pylori eradication treatment at 12 months. According to the analysis 
the mean response rate to placebo at 1 year was 28% (range 7-51%) and the mean response 
rate to H. pylori eradication 36% (range 21-58%). Many researchers thinks that eradication H. 
pylori might be a cost-effective intervention for FD. 
4. The aim of the study 
1. The main aim of the study was to compare the accuracy of serology tests (ELISA, 
HelicoTest) with the benchmark UBT in the detection of H. pylori infection in young 
dyspeptic patients age 20-45 who presented with chronic dyspeptic symptoms over 6 
months at the primary care setting. 
2. The additional aims of the study determine whether a correlation existed between the 
level of Ig G antibodies and positive UBT test.  
5. Material and methods 
The study was conducted from 2004-2006 in the primary care setting in Cracow. Each of the 
enrolled patients underwent the following procedures:  
 Detailed history 
 Physical examination 
 C13 Urease UBT test 
 Serological ELISA-DPC test 
 HelicoTest - a rapid test for quick detection of IgG antibodies  
 Epidemiological questionnaire using the Glasgow Dyspepsia Severity Score (GDSS) 
which assesses dyspepsia symptoms (10).  
The most frequent symptoms of dyspeptic patients were: epigastric pain, upper abdominal 
discomfort before and after a meal, and dysmotility-related symptoms (bloating, nausea, 
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belching, occasional heartburn). The study was approved by the Ethics Committee of the 
Jagiellonian University, and all participants gave written informed consent. The gold 
standard of diagnosis of H. pylori infection was based on a positive UBT test. Patients with 
alarm symptoms were not included into the study. 
Exclusion criteria included: weight loss, anaemia, hematemesis, melena, abdominal tumor, 
use of non-steroidal anti-inflammatory drugs, use of antibiotics or ranitidine bismuth citrate 
four weeks prior to the investigation, use of PPI two weeks and H2 blockers 48 hours prior 
to investigation. 
Statistical analysis was carried out using the STATISTICA and SAS programs. The 
agreement of the tests was assessed by three criteria: the percentage of incompatible results, 
the value of the kappa coefficient, and McNemara’s test for related dichotomous variables. 
P<0.05 was considered statistically significant. Distinguishing a positive or a negative H. 
pylori result was objective in UBT and positive ELISA was considered at the level of 1.00 
U/ml.  
6. Results 
The study group consisted of 159 patients. Patients characteristics are shown in (Tab.8).  
 
Study 
group 
Mean age Sex 
Smokers 
Non 
smokers 
34,79 
Female Men 
159 
patients 
(73,6%) (26,4%) (16,4%) (83,6%) 
Table 8. The study patient groups’ characteristics 
The men had higher level of Ig G antibodies than women see tab.9. 
 
Group 
[U/ml] 
Sex 
[U/ml] 
Female Men 
study 
[1,83] 
1,76 2,02 
Table 9. The mean level of Ig G antibodies depending on the patient’s sex. 
The majority of patients have moderate symptoms. Acute symptoms were only found in a 
minority of patients (Tab.10,11,12). The most common symptoms from the tested population 
are shown in the following tables. 
 
Study group 
159 
Type of dyspeptic symptoms (%) 
Severe Moderate Mild 
Not 
specific 
18.2 59.8 17 5.0 
Table 10. Severity of symptoms in the study population. 
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Study group (%) 
Upper abdominal 
pain 
Heartburn 
Discomfort in 
upper area 
Belching Nausea Flatulence 
76,1 62,2 68,5 50,3 32,7 59,8 
Table 11. The types of symptoms in study group. 
 
Study group 
Heartburn[%] Frequency of symptoms [%] 
yes/not Occasional Once a week Everyday 
62,7/37,3 35,4 15,8 11,4 
Table 12. The frequency of heartburn symptoms in the study group. 
UBT showed that in the study of 81 (50.9%) dyspeptic patients, were infected with H. pylori, 
and ELISA tests were positive in 79 (49.7%) of patients. HelicoTest was positive in 88 (55.3%) 
of patients (Fig.6).  
  
Fig. 6. The prevalence of H. pylori infection in the study group (p>0,05). 
The increasing antibody level on ELISA showed the increasing probability of returning a 
positive UBT. For ELISA tests a positive result was defined as an antibody level of 1.12 
(U/ml) using the Generalized Linear Model and 1.07 (U/ml) using the Generalized 
Additive Model. The IgG levels and the probability of H. pylori infection by UBT test is 
shown below (Fig.7). 
The HelicoTest showed the highest prevalence of H. pylori infection, but the mean ELISA 
level by positive HelicoTest and negative UBT was 0.86 U/ml. The kappa coefficient for 
study group was 0.92 for UBT and ELISA and 0.66 for UBT and HelicoTest. The McNemary 
test showed no statistical differences in prevalence of H. pylori infection (Tab.13). 
The majority of the young population tested had moderate dyspeptic symptoms. Analysis of 
the data showed little difference in detection of H. pylori among patients with acute, 
moderate, or mild dyspeptic symptoms, with patients with acute dyspeptic symptoms 
having the highest mean level of IgG (4.18 U/ml), ( Fig.8). 
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Fig. 7. The probability of H. pylori infection by UBT and IgG level in the study group by 
GAM and GLZ. 
 
 
 
 
Tests 
Study Group 
n               x2                  p 
UBT test 
and ELISA 
159 0,29 0,593 
UBT test 
and HelicoTest 
159 2,33 0,157 
 
 
Table 13. Test McNemary – for study group UBT, ELISA and HelicoTEST.  
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Fig. 8. The mean IgG level (U/ml) with mild, moderate and severe dyspeptic symptoms.  
7. Discussion  
Dyspepsia is an extremely common disorder affecting an estimated 40% of the world’s 
population. Only a minority of patients who experience symptoms will seek medical care, 
but dyspepsia still accounts for 5-7% of all visits to primary care physicians. Approximately 
60% of young individuals reporting symptoms have FD, with the majority of these having 
no underlying organic cause of their symptoms. In countries with a high prevalence of H. 
pylori  infection the “test and treat strategy” is a major way to manage undiagnosed 
dyspepsia.  The economic models suggest that in populations of low H. pylori prevalence 
managing dyspepsia with empiric acid suppression therapy is a more cost-effective method.  
Noninvasive testing for H. pylori infection is the main mode of testing for the young 
dyspeptic population. The correlation between the level of H. pylori IgG antibodies and UBT 
test is largely unknown as there is little research available which examines undiagnosed 
dyspepsia in patients under 45 years of age in a primary care setting. H. pylori infection is 
thought to be the most common factor for morbidity and mortality in upper digestive tract 
diseases. 
We aimed to determinate the prevalence H. pylori infection and dyspeptic syndrome. In the 
USA patients under 55, and in Canada patients under 50, along with any patients suffering 
from dyspepsia without alarm symptoms should be tested for H. pylori infection and treated 
appropriately to control the symptoms (6,25). The optimal age threshold for endoscopy is 
unclear, and it is good to not that over half of the endoscopy results will not show any 
organic changes in standard endoscopy.  
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Research on high magnifying endoscopy and chromoendoscopy has showed that new 
methods are superior to standard endoscopy for diagnosis of H. pylori gastritis and finding 
some mucosal and capillary structures (34). 
Noninvasive H. pylori testing is even more important now than in the past because 
dyspeptic problems are increasingly seen in the primary care setting, and diagnosis of H. 
pylori infection is important to the treatment of these patients. Past studies have shown that 
in a population with a high prevalence of H. pylori infection, the “test and treat” strategy is 
the best option (12). Overuse NSAID’s and in patients with risk factors, using 
cardioprotective doses of aspirin, eradication of H. pylori can be recommended. 
The new classification of functional dyspepsia by Suzuki is based on a patient-centered 
approach based on the highest index of symptoms (24,28). We still do not know why the 
symptoms of dyspepsia fluctuate in the short-term. The strategy of rescreening H. pylori 
infection and eradication in high-risk population has already started (11,30,33).  
The European Helicobacter Study Group (EHSG) was founded in 1987 to promote  
multidisciplinary research into the pathogenesis of H. pylori as a cause of upper 
gastrointestinal tract diseases, and how the treatment of H. pylori will aid in the prevention 
of gastric cancer (16).The EHSG has organized many annual consensus meetings and 
published current concepts regarding the management of H. pylori infection in Maastricht I,  
II, III and Maastricht IV (18,19,20).  
The data in this study confirms that there is a correlation between the level of IgG antibodies 
and positive UBT test. There are some patients with dyspepsia and borderline results for H. 
pylori tests, and this is a problem that will require more research in the future (22). Right 
now, we strongly advise repeating the test in those patients whose symptoms persist 
because there is a correlation in the age and the prevalence of H. pylori infection in young 
dyspeptic patients and positive UBT test (21). There is a need to retest the population with 
dyspeptic symptoms and positive HelicoTest and negative UBT.  
8. Conclusion  
The level of IgG ELISA is a good predictor of probability of positive UBT. Serological testing 
by HelicoTest showed the highest prevalence H. pylori infection in young undiagnosed 
dyspeptic patients. Follow-up of these patients will be important to observe symptom relief 
and fluctuation in young dyspeptic patients.  
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